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Abstract
Introduction 
Healthy People 2010 (HP 2010) objectives call for a 38% 
reduction in the prevalence of diagnosed diabetes mellitus, 
type 1 and type 2, by the year 2010. The process for setting 
this objective, however, did not focus on the achievability 
or the compatibility of this objective with other national 
public health objectives. We used a dynamic simulation 
model to explore plausible trajectories for diabetes preva-
lence in the wake of rising levels of obesity in the U.S. 
population. The model helps to interpret historic trends in 
diabetes prevalence in the United States and to anticipate 
plausible future trends through 2010.
Methods
We conducted simulation experiments using a computer 
model  of  diabetes  population  dynamics  to  1)  track  the 
rates at which people develop diabetes, are diagnosed with 
the disease, and die, and 2) assess the effects of various 
preventive-care interventions. System dynamics modeling 
methodology based on data from multiple sources guided 
the analyses.
Results
With the number of new cases of diabetes being much 
greater than the number of deaths among those with the 
disease, the prevalence of diagnosed diabetes in the United 
States is likely to continue to increase. Even a 29% reduc-
tion in the number of new cases (the HP 2010 objective) 
would only slow the growth, not reverse it. Increased dia-
betes detection rates or decreased mortality rates — also 
HP 2010 objectives — would further increase diagnosed 
prevalence.
Conclusion
The HP 2010 objective for reducing diabetes prevalence 
is  unattainable  given  the  historical  processes  that  are 
affecting incidence, diagnosis, and mortality, and even a 
zero-growth future is unlikely. System dynamics model-
ing  shows  why  interventions  to  protect  against  chronic 
diseases  have  only  gradual  effects  on  their  diagnosed 
prevalence.
Introduction
In each of the past three decades, national public health 
objectives  in  the  United  States  have  been  set  10  years 
into the future and published as health objectives for the 
nation  (1-3).  These  objectives  define  specific  numerical 
targets for reductions in most major health problems as 
well as for increases in the prevalence of health-promot-
ing behaviors. J. Michael McGinnis, MD, a chief architect 
of  the  objective-setting  enterprise,  asserts  that,  “Of  the 
broad  range  of  governmental  responsibilities  in  public 
health, perhaps none is more fundamental than the obli-
gation to provide perspective and direction to guide health 
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programs along a productive course — the agenda-setting 
function” (4).
Considering the widespread use and significance of the 
Healthy People (HP) objectives for planning and evaluat-
ing public health work at all levels of practice, health care 
practitioners  may  expect  national  health  objectives  to 
be feasible, that is, to be achievable within the specified 
time frame. However, HP objectives may not always meet 
this feasibility standard (5). The objectives for 2010, in 
particular, were set on the basis of a policy goal of elimi-
nating health disparities among racial and ethnic groups. 
Consequently,  planners  used  a  “better  than  the  best” 
approach wherein each objective was set at a level better 
than that of the “best” (i.e., most healthy) racial or ethnic 
group. That approach advanced health equity as an impor-
tant  philosophical  ideal,  which,  in  turn,  generated  an 
ambitious aspiration for health policy-making. But it may 
not have yielded, in all cases, objectives that are achiev-
able and compatible with other public health objectives. 
In addition, the practice of conducting midcourse reviews 
and periodic evaluations of progress toward meeting HP 
objectives may convey the impression that the numerical 
targets are actually achievable by 2010 and are therefore 
meaningful referents for assessing progress (6,7).
Questioning whether long-range objectives can be met 
raises  additional  questions  about  the  analytic  proce-
dures that guide objective-setting itself, which is a com-
plicated  dimension  of  public  health  science  that  is  still 
poorly understood. In this article, we illustrate how sys-
tem dynamics (SD) simulation modeling can inform the 
development and understanding of national public health 
objectives. Specifically, we use an SD model to 1) interpret 
the historic prevalence record of diagnosed diabetes (as 
used throughout this article, diabetes refers to diabetes 
mellitus, types 1 and 2) in the United States; and 2) antici-
pate the future prevalence of diabetes through 2010 under 
various scenarios.
Figure 1 displays the observed trend in the prevalence 
of  diagnosed  diabetes  (diagnosed  prevalence)  per  1000 
population from 1980 through 2003 (8). It also illustrates 
the two paths that HP 2000 and HP 2010 objectives indi-
cate  for  diabetes  prevalence  (2,3).  In  1990,  after  three 
decades in which diabetes prevalence increased (9), the 
HP 2000 baseline was set on the basis of 1987 data (point 
A), and the HP 2000 objective called for an 11% reduction 
in prevalence by 2000 (point B). Instead, diagnosed preva-
lence increased by 33% between 1987 and 2000 (from point 
B to point D). The official final review of HP 2000 showed 
that prevalence “moved away from target” (10) by 367% 
(calculated by comparing the D-to-B gap with the A-to-B 
target decrease).
 
Figure 1. Diagnosed prevalence of diabetes per 000 total population, 
United States, 980–2003 (8), with Healthy People 2000 and Healthy 
People 2010 objectives (2,3), and simulation model output, for 2003–
200 (3).
The HP 2010 objective, which was based on 1997 data, 
called for an even more ambitious 38% reduction in dia-
betes prevalence, from 39.2% to 25.0% (point C to E). But 
again, surveillance data revealed a worsening trajectory. 
From 1997 to 2003, diabetes prevalence increased another 
25% (point C to point F), making the 2010 objective even 
more unattainable.
What accounts for these discrepancies between preva-
lence  objectives  and  actual  prevalence  data?  Are  they 
due  to  poor  performance  of  the  overall  national  health 
protection strategy, which includes an array of separately 
focused programs and policies (11)? Or are they perhaps 
the  result  of  a  flaw  in  how  the  numerical  targets  are 
derived? If the latter is the case, what is a more plausible 
estimate of the actual trajectory of U.S. diabetes preva-
lence through 2010? 
Methods
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sought to answer these questions by conducting a series 
of  simulation  experiments  using  an  existing  SD  model 
designed specifically to explore the population dynamics 
of diabetes among adults in the United States (12,13). The 
model  was  designed  to  explore  the  incremental  effects 
various  possible  policy  interventions  could  have  on  the 
burden of diabetes. To achieve this result, the SD model, 
unlike  other  diabetes  models  (for  example,  a  Markov 
model by Honeycutt et al [14]), comprehensively accounts 
for a chain of population flows that begins when a person 
becomes at risk for diabetes and continues through initial 
onset, diagnosis, progression, and death. Such breadth of 
scope allows the SD model to anticipate nonlinear changes 
in  variables,  such  as  the  incidence  rate,  that  narrower 
models would miss (22).
We developed the SD diabetes model using well-estab-
lished techniques for model formulation and testing (15-
21). Data  from  the  National  Health  Interview  Survey, 
the National Health and Nutrition Examination Survey 
(NHANES),  the  Behavioral  Risk  Factor  Surveillance 
System, the U.S. Census Bureau, and publications in the 
scientific  literature  provided  the  empirical  foundation 
for parameter selection and estimation. We were able to 
draw  some  parameter  estimates  directly  from  available 
information,  and  we  obtained  others  through  a  process 
of historical curve-fitting analogous to statistical regres-
sion. (For more detail on the sources and methods used 
in determining the parameters for the SD diabetes model, 
see references 13 and 22.)
Structure of the diabetes system 
The SD diabetes model specifies how population groups 
accumulate in several states of health (e.g., prediabetes, 
uncomplicated diabetes, complicated diabetes) along with 
the rates at which people flow from one state to another. 
The full model contains many such states and rates (13); 
however, in Figure 2 we show only a simplified and generic 
view for explanatory purposes.
Figure 2 depicts a generic stock-and-flow structure that 
can  be  used  to  illustrate  the  diagnosed  prevalence  for 
any disease. One may think of the box labeled diagnosed 
prevalence as a bathtub in which the water level repre-
sents the number of people who have been diagnosed with 
a disease (23). The rate at which a condition is diagnosed, 
diagnosed onset, is analogous to the rate at which water 
flows into the bathtub. The rates of recovery or death for 
people with diagnosed disease are analogous to the rates 
at  which  water  flows  out  of  the  bathtub  through  two 
separate  drains.  As  Figure  2  illustrates,  all  changes  in 
diagnosed prevalence must be accounted for by changes in 
these related flows. (For a complete accounting, the flows 
of births, migration, and recovery among the undiagnosed, 
as well as deaths among those without the disease and 
deaths among the undiagnosed, would be needed, but for 
clarity these are not depicted in Figure 2.)   
Following is a summary of how the generic elements of 
Figure 2 relate specifically to diabetes:
• Diagnosed prevalence: Figure 1 provides historical data 
for  1980  through  2003.  In  2000,  about  12.0  million 
people of all ages in the United States had diagnosed 
diabetes; of these 12.0 million people, 98% were adults 
aged 20 years and older. This percentage translates to 
about 4.4% of the total population and 6.0% of the adult 
population (14,24).
• Diagnosed onset: About 880,000 people were newly diag-
nosed with diabetes in 1997, and that figure rose to 1.1 
million by 2000. Of these 1.1 million people, more than 
96% were adults. This percentage translates to a diag-
nosis rate among the adult population of about 5.2 per 
1000 in 2000 (14,24).
• Recovery: Recovery is a significant factor in prevalence 
calculations for many acute illnesses; however, in diabe-
tes, as for all chronic diseases without a cure, it is not a 
factor.
• Deaths among people with diagnosed diabetes: Diabetes, 
like many other chronic diseases, has a relatively low 
annual death rate. In 2000, of the 12.0 million people 
with diagnosed diabetes, about 500,000 (4.2%) died (14). 
Of these deaths, 213,000 (a rate of 1.8% per year among 
Americans with diabetes) were related to complications 
of the disease (24).
 
Figure 2. Generic stock-and-flow structure for diagnosed prevalence of a 
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• Undiagnosed prevalence: Since 1976, researchers have 
tested blood glucose levels in random samples of adults 
without  diagnosed  diabetes  who  were  participants  in 
the periodic NHANES (9) to determine if they had dia-
betes. By dividing the number of people found to have 
diabetes by the total number of people tested, research-
ers estimated the fraction of Americans with diabetes 
whose disease was undiagnosed for each of the following 
NHANES  periods:  1976–1980:  38%;  1988–1994:  36%; 
and 1999–2000: 29% (25).
• Initial Onset: There is no actual measure of the rate of 
initial onset of diabetes (i.e., the number of people per 
year who develop diabetes) as opposed to the rate of dia-
betes diagnosis. However, we estimated the initial onset 
rate by combining the data described above on diagnosed 
prevalence,  undiagnosed  prevalence,  and  death  using 
the causal logic of Figure 2. According to our estimates, 
in 2000, 1.25 million U.S. adults experienced the initial 
onset of diabetes, a rate of 6.0 people per 1000.
• Population  without  diabetes: This  category  includes 
people with normal blood glucose levels and those with 
prediabetes, a condition in which levels are moderately 
elevated (26). According to estimates based on blood test 
data from NHANES 1988–1994, about 40% of Americans 
aged 40 to 74 years had prediabetes (24,26). We extrapo-
lated  this  figure  to  the  rest  of  the  adult  population, 
using historical data on age-specific diabetes incidence 
(14), to estimate differences in prediabetes prevalence 
between people aged 18 to 39 years and those aged 75 
and older. Projecting forward in time, we estimated that 
at least 52 million (25%) of Americans aged 18 and older 
had prediabetes in 2000.  
Exploring scenarios for the future 
The SD model employed in our simulations tracks the 
flows and accumulations of people with normal blood glu-
cose levels, undiagnosed or diagnosed prediabetes, undi-
agnosed or diagnosed diabetes without complications, and 
undiagnosed or diagnosed diabetes with complications. In 
the model, we specify key factors — some of them potential-
ly amenable to policy intervention — that may change over 
time and that affect the model’s population flows. These 
variable  policy  factors  include  the  prevalence  of  obesity 
(i.e., the leading modifiable risk factor for diabetes); the 
prevalences  of  glycemic  screening,  prediabetes  manage-
ment, and diabetes management; as well as the percent-
age of the population with access to preventive care (13). A 
scenario involves specified future values for each variable 
factor. The  model  can  then  simulate  the  consequences 
of any given scenario for future trajectories of diagnosed 
prevalence and other measures of disease burden.
Results
A status quo scenario 
Beginning  in  2004,  results  from  the  first  simulation 
experiment  focus  on  a  status  quo  future,  in  which  we 
assumed no further changes in the scope or effectiveness 
of prevention, detection, or management efforts or in the 
prevalence of obesity. In Figure 1, the line marked status 
quo (from point F to G) shows the projected prevalence 
of diagnosed diabetes through 2010 under these assump-
tions. Diagnosed prevalence is projected to rise through-
out this period because the inflow of people with newly 
diagnosed diabetes is projected to exceed the rate at which 
people are dying. Under this scenario, the prevalence of 
diagnosed diabetes is projected to increase 21%, from 48.9 
per 1000 in 2003 to 59.1 per 1000 in 2010 (point F to G).
A straightforward comparison of the estimates of inflow 
(diagnosis) and outflow (death) explains why the upward 
trend in diabetes prevalence, which began around 1990, 
will not soon abate. If the diagnosed onset rate in 2000 
of  approximately  1.1  million  cases  per  year  and  the 
death  rate  of  about  500,000  per  year  were  to  stay  the 
same,  we  projected  that  the  diagnosed  prevalence  will 
continue to increase. Although the model suggests that 
this gap between inflow and outflow is gradually closing, 
the inflow of diagnosed diabetes onset would have had to 
drop substantially (e.g., by about 50% in 2006) just for 
diagnosed prevalence to stop increasing, let alone to begin 
decreasing.
Accounting for program and policy interventions   
Our SD model reveals certain insights about the long-
term effects of interventions to reduce onset, boost detec-
tion, or better manage diabetes. For example, aside from 
reducing  prevalence,  another  HP  2010  objective  calls 
for the percentage of people with diagnosed diabetes to 
increase  from  68%  to  80%  (Objective  5-4)  (3).  Such  an 
increase in diagnoses would, in terms of Figure 2, increase 
the  inflow  of  people  diagnosed  with  the  disease.  Thus, 
the prevalence of diagnosed diabetes would also increase. 
Figure 1 quantifies the effect of this scenario as the VOLUME 4: NO. 3
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difference between points H and G (i.e., 63.2 vs 59.1 in 
the year 2010).
Another HP 2010 objective calls for an 11% reduction in 
the diabetes-attributable death rate (Objective 5-6) (3), a 
result presumably to be achieved through improved dis-
ease management. As Figure 2 indicates, a reduction in 
deaths would also increase diagnosed prevalence because 
more people with the disease would remain alive. (Figure 
1  does  not  display  a  curve  for  this  scenario  because  it 
overlaps the status quo line [i.e., 59.3 vs 59.1 in the year 
2010]). 
The inconsistency in these HP 2010 objectives for dia-
betes is clear: meeting the objectives for increasing the 
diagnosis rate or decreasing the mortality rate would tend 
to increase the prevalence of diagnosed diabetes.
One type of public health intervention that could possi-
bly reduce the diagnosed prevalence of diabetes would be 
one aimed at reducing the initial onset rate. HP 2010 calls 
for a 29% reduction in the number of new diabetes diagno-
ses per 1000 (Objective 5-2) (3), presumably to be achieved 
through enhanced efforts to detect and manage prediabe-
tes. This effort would, perhaps, be combined with efforts to 
reduce the prevalence of obesity in the general population. 
A reduction in the inflow resulting from diagnosed disease 
onset is clearly a move in the right direction because it 
leads to a lower diagnosed prevalence than would be the 
case under the status quo (i.e., without an intervention to 
reduce disease onset). But a reduction in diagnosed preva-
lence relative to the status quo is not the same as an abso-
lute reduction over time — an actual reversal of growth. 
We described previously how a straightforward compari-
son of the inflow and outflow rates in Figure 2 indicates 
that a reduction in the onset of diagnosed diabetes on the 
order of 50% would be required to halt the growth in diag-
nosed prevalence. However, the question still remains: to 
what extent could a significant reduction in onset at least 
slow the growth of diagnosed prevalence? 
To  address  this  question,  we  simulated  an  interven-
tion begun in 2003 that would reduce the rate of diabetes 
onset 29% below its 1997 level by 2010. In this scenario, 
as shown in Figure 1, the prevalence of diagnosed diabetes 
increases by 7% (from F to I) per 1000 population from 
2003 to 2010 as compared with increasing by 21% (from 
F to G) in the status quo scenario (i.e., 52.3 vs 59.1 in the 
year 2010). This slower growth in the number of people 
with  diagnosed  diabetes  certainly  would  improve  the 
overall disease picture, but it would not yield a decline in 
diabetes prevalence.
The simulation modeling thus helps quantify what the 
stock-and-flow logic of Figure 2 and previously described 
numerical analysis suggested: that the HP 2010 target of 
a 29% reduction in the rate of diabetes onset is too modest 
a reduction to achieve the desired reduction in prevalence 
and can only slow its growth.
The SD model can also be used to explore more extreme 
possibilities. For example, what would happen if initial 
onset of undiagnosed diabetes had dropped suddenly to 
zero during 2004? Even under this impossible-to-achieve 
scenario,  diagnosed  prevalence  would  decrease  by  only 
14% from 2003 to 2010 (data not shown). This decrease 
is relatively small partly because cases of diabetes will 
continue to be diagnosed during this period even though 
initial onset has ceased, and partly because of the rela-
tively low death rate among people with diabetes (about 
4% per year). Thus, even this most optimistic scenario of a 
14% reduction in diagnosed prevalence of diabetes during 
2003 through 2010 falls far short of the 38% objective of 
HP 2010.
Discussion
Charting plausible paths 
Findings  from  our  study  indicate  that  the  HP  2010 
objective  for  reducing  diagnosed  diabetes  prevalence  by 
38% will not be achieved — not because of ineffective or 
underfunded  health  protection  efforts  but  because  the 
objective itself is unattainable. Moreover, if current invest-
ments in diabetes screening and disease management con-
tinue to succeed in diagnosing a greater number of people 
and in enabling people to live longer with the disease, then 
diagnosed prevalence will move still farther away from the 
HP 2010 target.
In setting long-range numerical targets for health objec-
tives, particularly those that may be viewed as interven-
tion outcomes, it is important to recognize that the diag-
nosed  prevalence  metric  is  subject  to  misinterpretation 
and to unrealistic expectations for two basic reasons:
• The  task  of  setting  plausible  prevalence  objectives VOLUME 4: NO. 3
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requires  an  understanding  that  the  growth  in  preva-
lence of many chronic diseases can, at best, be slowed, 
and it can be reversed only gradually. This is because the 
number of deaths from chronic disease is small relative 
to increases resulting from disease onset (perhaps, as in 
the case of diabetes, because of a decades-long increase 
in  the  at-risk  population),  and  there  is  no  significant 
reduction as a result of people recovering from chronic 
diseases. Therefore, the task of reducing prevalence is 
comparable to attempting to return a fast-moving train 
to a station that it passed miles back: the first step is to 
slow the train down, not to reverse its direction.
• As a result of successful interventions to increase dis-
ease detection and management, people are living longer 
with chronic diseases rather than dying prematurely. 
But  by  increasing  detection  and  extending  life,  such 
interventions  also  have  the  effect  of  increasing  diag-
nosed prevalence of these diseases. The only practical 
way of slowing the growth in diagnosed prevalence is 
through health protection programs that reduce the rate 
of disease onset. However, onset must not only decline. 
It must fall far enough to more than offset the increase 
in disease prevalence resulting from improved detection 
and management. It will be impossible to set achievable 
prevalence-reduction objectives unless this relationship 
is taken into consideration.
If prevalence objectives are to be attainable within their 
specified time frame, it is important first to recognize what 
the disease trajectory would be under status quo assump-
tions and then to factor in the effects of any planned inter-
ventions, recognizing that measurable success in one area 
(e.g.,  an  increase  in  the  percentage  of  cases  diagnosed) 
may reduce apparent progress in others (e.g., decreased 
prevalence). In the case of diabetes, we found in our simu-
lation  experiments  that  under  current  conditions,  that 
is, without any new interventions, diagnosed prevalence 
would increase 21% from 2003 to 2010. Proposed detection 
and management initiatives, if successful, would increase 
that number even further. If disease prevalence is to serve 
as a benchmark for assessing the performance of national 
public  health  interventions,  then  prevalence-reduction 
goals must account for the compounding effects of success-
ful disease detection and management interventions.
Recognizing the benefits of formal modeling 
Simulation  modeling  helps  improve  our  collective 
understanding  of  health  and  disease  dynamics,  and  in 
turn supports the development of long-range objectives 
that are both achievable and mutually consistent. Such 
models  enable  planners  and  policy  makers  to  explore 
for  themselves  the  plausible  short-  and  long-term  con-
sequences of historic trends and to compare the effects 
of  alternative  interventions  before  committing  limited 
resources. For that reason, diabetes program planners in 
Vermont have worked with members of the CDC Diabetes 
System Modeling team to use the model described here as 
a support for their efforts to set plausible and internally 
consistent objectives for diabetes-related outcomes at the 
state  level  (28,29).  Planners  in  Minnesota,  California, 
Alabama, Tennessee, and Florida are currently exploring 
similar uses.
Without  the  reality  checks  available  through  formal 
simulation  experiments,  long-range  target-setting  may 
fall  prey  to  the  weaknesses  of  flawed  and  sometimes 
biased intuition (mental models) (17,23). Popular concep-
tions  about  how  certain  phenomena  change  over  time 
may often fail to account for real-world sources of iner-
tia and delay and may suggest that things can change 
more  rapidly  than  is  actually  possible.  The  prevalence 
of a chronic disease like diabetes changes only gradually 
because, as noted above, people with such conditions die 
at a relatively slow rate, and there is currently no cure 
for these conditions. In this respect, chronic diseases are 
unlike many acute infectious diseases such as influenza or 
measles, whose victims do not linger in the disease condi-
tion for years but instead recover or die relatively quickly. 
For such acute diseases, the large outflow creates a close 
correlation  between  decreases  in  the  rate  of  onset  and 
in diagnosed prevalence. For chronic illnesses, however, 
decreases  in  onset  rates  do  not  correlate  with  immedi-
ate decreases in prevalence; instead, they correlate with 
prevalence increasing more slowly.
Those working to prevent and manage chronic diseases 
may  use  stock-and-flow  diagrams  to  develop  a  clearer 
understanding  of  the  characteristic  dynamics  of  these 
diseases. In addition, simulation experiments may bring 
new insights to the task of setting realistic and achievable 
goals for the nation’s health. That approach could help 
ensure that numerical objectives are mutually consistent 
and achievable within their stated time frames. The objec-
tives may still be difficult to achieve in practice and in that 
sense may be aspirational. But even aspirational objec-
tives can and should be crafted in a way that is consistent, 
logical, and feasible given the causal structure of the sys-VOLUME 4: NO. 3
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tem and the historical processes under way, particularly 
those responsible for the pattern of increasing incidence 
and diagnosis, as well as declining mortality.
Although simulation models can help improve our under-
standing of chronic disease dynamics, they have several 
inherent limitations. All models are incomplete simplifi-
cations of reality, and their conclusions are affected both 
by structural boundaries and by the uncertainties of the 
data with which they are calibrated (29). Techniques such 
as boundary critique (30) and sensitivity testing (17,31) 
can  be  used  to  assess  the  extent  to  which  models  may 
be affected by these simplifications and uncertainties. In 
the case of the diabetes SD model, sensitivity testing sug-
gests that the magnitudes of its simulated futures, such 
as those seen in Figure 1, are subject to some imprecision 
because of uncertainties about input parameters, but that 
the directions of change and thus our general findings are 
unaffected by these uncertainties.
Even with their inevitable imprecision and incomplete-
ness, simulation models can enhance learning and decision 
making, and that is their primary purpose (17,32). These 
tools can improve our collective understanding about how 
interventions will affect health indicators over many years 
within the complex systems of cause and effect that shape 
the public’s health.
Acknowledgments
This  work  was  funded  through  the  Association  of 
Schools of Public Health Cooperative Agreement by CDC’s 
Division  of  Diabetes  Translation  (DDT)  and  Division  of 
Adult and Community Health, in collaboration with the 
Rollins School of Public Health at Emory University.
Author Information
Corresponding  Author:  Bobby  Milstein,  PhD,  MPH, 
Syndemics  Prevention  Network,  Centers  for  Disease 
Control and Prevention, 4770 Buford Hwy NE, Mailstop 
K-64,  Atlanta,  GA 30341.  Telephone:  770-488-5528.  E-
mail: bmilstein@cdc.gov.
Author  Affiliations:  Andrew  Jones,  Sustainability 
Institute, Asheville, NC; Jack B. Homer, Homer Consulting, 
Voorhees, NJ; Dara Murphy, Centers for Disease Control 
and Prevention, Atlanta, Ga; Joyce Essien, Rollins School 
of  Public  Health,  Emory  University,  Atlanta,  Ga;  Don 
Seville, MS, Sustainability Institute, Hartland, Vt.
References
 1.  United  States  Public  Health  Service.  Promoting 
health, preventing disease: objectives for the nation. 
Washington  (DC):  U.S.  Department  of  Health  and 
Human Services, Public Health Service; 1980.
 2.  United States Public Health Service. Healthy people 
2000: national health promotion and disease preven-
tion objectives. Washington (DC): U.S. Department of 
Health and Human Services; 1990.
 3.  United States Public Health Service. Healthy people 
2010. Washington (DC): U.S. Department of Health 
and Human Services; 2000.
 4.  McGinnis JM. Setting nationwide objectives in disease 
prevention and health promotion: the United States 
experience. In: Holland WW, Detels R, Knox G, edi-
tors. Oxford textbook of public health. Oxford (UK): 
Oxford University Press; 1985.
 5.  Mendez D, Warner KE. Smoking prevalence in 2010: 
why  the  healthy  people  goal  is  unattainable.  Am  J 
Public Health 2000;90(3):401-3.
 6.  Mukhtar Q, Jack L Jr, Martin M, Murphy D, Rivera 
M. Evaluating progress toward Healthy People 2010 
national diabetes objectives. Prev Chronic Dis [serial 
online] 2006 Jan.
 7.  Healthy People midcourse review. Washington (DC): 
U.S.  Department  of  Health  and  Human  Services; 
2006.
 8.  Centers for Disease Control and Prevention. National 
Health  Interview  Survey  (NHIS).  Hyattsville  (MD): 
National Center for Health Statistics; 2004.
 9.  Kenny  S,  Aubert  R,  Geiss  L.  Prevalence  and  inci-
dence of non-insulin-dependent diabetes. In: Harris M, 
Cowie C, Reiber G, Boyko E, Stern M, Bennett P, edi-
tors. Diabetes in America. 2nd ed. Washington (DC): 
U.S. Government Printing Office; 1995. p. 47-68.
10. Healthy People 2000 final review: national health pro-
motion and disease prevention objectives. Hyattsville 
(MD): U.S. Department of Health and Human Services, 
Centers for Disease Control and Prevention, National 
Center for Health Statistics; 2001.
11. Murphy D, Chapel T, Clark C. Moving diabetes care 
from science to practice: the evolution of the National 
Diabetes Prevention and Control Program. Ann Intern VOLUME 4: NO. 3
JULY 2007
8  Centers for Disease Control and Prevention • www.cdc.gov/pcd/issues/2007/jul/06_0070.htm
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, 
the Public Health Service, the Centers for Disease Control and Prevention, or the authors’ affiliated institutions. Use of trade names is for identification only 
and does not imply endorsement by any of the groups named above.
Med 2004;140(11):978-84.
12. Homer  J,  Jones  A,  Seville  D,  Essien  J,  Milstein  B, 
Murphy D. The CDC diabetes system modeling proj-
ect: developing a new tool for chronic disease preven-
tion and control. Conference proceeding from the 22nd 
International  Conference  of  the  System  Dynamics 
Society. 2004 Jul 25-29; Oxford, UK.
13. Jones AP, Homer JB, Murphy DL, Essien JD, Milstein 
B,  Seville  DA.  Understanding  diabetes  population 
dynamics  through  simulation  modeling  and  experi-
mentation. Am J Pub Health 2006;96(3):488-94.
14. Honeycutt AA, Boyle JP, Broglio KR, Thompson TJ, 
Hoerger TJ, Geiss LS, et al. A dynamic Markov model 
for forecasting diabetes prevalence in the United States 
through 2050. Health Care Manag Sci 2003;6(3):155-
64.
15. Forrester JW. Industrial dynamics. Cambridge (MA): 
MIT Press; 1961.
16. Forrester JW. Urban dynamics. Cambridge (MA): MIT 
Press; 1969.
17. Sterman  JD.  Business  dynamics:  systems  thinking 
and modeling for a complex world. Boston (MA): Irwin 
McGraw-Hill; 2000.
18. Homer JB, Hirsch GB. System dynamics modeling for 
public  health:  background  and  opportunities.  Am  J 
Public Health 2006;96(3):452-8.
19. Milstein B, Homer J. Background on system dynamics 
simulation modeling, with a summary of major public 
health studies. Atlanta (GA): Syndemics Prevention 
Network, Centers for Disease Control and Prevention; 
2005.
20. Homer  JB,  Oliva  R.  Maps  and  models  in  system 
dynamics:  a  response  to  Coyle.  System  Dynamics 
Review 2001;17(4):347-55.
21. Sterman  JD.  System  dynamics  modeling:  tools  for 
learning in a complex world. California Management 
Review 2001;43(4):8-25.
22. Homer J. Reference guide for the CDC Diabetes System 
Model. Atlanta (GA): Centers for Disease Control and 
Prevention, Division of Diabetes Translation; 2006.
23. Booth-Sweeney LB, Sterman JD. Bathtub dynamics: 
initial results of a systems thinking inventory. System 
Dynamics Review 2000;16(4):249-86.
24. National diabetes fact sheet. Atlanta (GA): Centers for 
Disease Control and Prevention; 2005. Available from: 
http://www.cdc.gov/diabetes/pubs/estimates.htm
25. Gregg EW, Cadwell BL, Cheng YJ, Cowie CC, Williams 
DE, Geiss L, et al. Trends in the prevalence and ratio 
of  diagnosed  to  undiagnosed  diabetes  according  to   
obesity  levels  in  the  U.S.  Diabetes  Care  2004;27(12):2806-
12.
26. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo 
R, Kahn R, et al. Follow-up report on the diagnosis of 
diabetes mellitus. Diabetes Care 2003;26(11):3160-7.
27. Murphy D, Homer J, Nanavati P, Daves S. Modeling 
population dynamics: diabetes. Conference proceeding 
from the Diabetes and Obesity Conference. 2006 May 
16-19; Denver, CO.
28. Edelman  R.  Vermont’s  experience  with  diabetes 
system  modeling.  Conference  proceeding  from  the 
Diabetes  and  Obesity  Conference.  2006  May  16-19; 
Denver, CO.
29. Sterman  JD.  All  models  are  wrong:  reflections  on 
becoming  a  systems  scientist.  System  Dynamics 
Review 2002;18(4):501-31.
30. Ulrich  W.  Boundary  critique.  In:  Daellenbach  HG, 
Flood  RL,  editors.  The  informed  student  guide  to 
management science. London (UK): Thomson; 2002. p. 
41-2.
31. Forrester JW, Senge PM. Tests for building confidence 
in system dynamics models. In: Legasto A, Forrester 
JW, Lyneis JM, editors. System Dynamics. New York 
(NY): North-Holland; 1980. p. 209-28.
32. Sterman  JD.  Learning  from  evidence  in  a  complex 
world. Am J Public Health 2006;96(3):505-14.